Iressa Enhances Radiotherapy in Colorectal Cancer
Author Information
Author(s): Williams K J, Telfer B A, Stratford I J, Wedge S R
Primary Institution: University of Manchester
Hypothesis
Does ZD1839 enhance the effectiveness of radiotherapy in colorectal cancer treatment?
Conclusion
The study found that ZD1839 significantly improves the anti-tumor effects of radiotherapy in colorectal cancer models.
Supporting Evidence
- ZD1839 significantly increased the anti-proliferative effect of radiation on LoVo cells in vitro.
- Combination treatment with ZD1839 and radiotherapy led to a greater tumor growth inhibition in mice compared to either treatment alone.
- The radio-potentiating effect of ZD1839 was more pronounced with fractionated radiation treatment.
Takeaway
This study shows that a drug called Iressa can make radiation therapy work better for treating certain types of cancer.
Methodology
The study used in vitro and in vivo models to evaluate the effects of ZD1839 combined with radiotherapy on colorectal cancer cells.
Limitations
The study was conducted in animal models, which may not fully replicate human responses.
Participant Demographics
Nude mice bearing LoVo colorectal cancer xenografts were used in the study.
Statistical Information
P-Value
0.002
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website